Exploring anti-fibrotic drugs: Focusing on an ex vivo model of fibrosis

Medicine and Dentistry

• Ex Vivo 100%
• Fibrosis 100%
• Fibrogenesis 100%
• Disease 66%
• Disease Model 66%
• Mediator 66%
• Liver Fibrosis 66%
• Tissue Slice 66%
• Combination Therapy 33%
• Chronic Disease 33%
• Clinical Study 33%
• Nonalcoholic Fatty Liver 33%
• Kidney Fibrosis 33%
• Extracellular Matrix 33%
• Transforming Growth Factor Beta 33%
• Platelet Derived Growth Factor 33%
• Reactive Oxygen Species 33%
• Liver Slice 33%
• Bone Morphogenetic Protein 33%
• Mitogen Activated Protein Kinase P38 33%
• Galunisertib 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Disease 100%
• Disease Model 100%
• Fibrosis 100%
• Liver Fibrosis 100%
• Drug Discovery 50%
• Drug Development 50%
• Clinical Study 50%
• Combination Therapy 50%
• Chronic Disease 50%
• Nonalcoholic Fatty Liver 50%
• Reactive Oxygen Metabolite 50%
• Platelet Derived Growth Factor 50%
• Transforming Growth Factor Beta 50%
• Kidney Fibrosis 50%
• Mitogen Activated Protein Kinase P38 50%
• Bone Morphogenetic Protein 50%
• Galunisertib 50%

Keyphrases

• Fibrous Matrix 20%